Alnylam’s Fitusiran gains FDA approval as a first RNAi therapeutic for hemophilia, while Vertex discontinues its innovative insulin-producing …
Alnylam’s Fitusiran gains FDA approval as a first RNAi therapeutic for hemophilia, while Vertex discontinues its innovative insulin-producing …
The FDA approval of Alnylam’s Fitusiran marks a milestone in RNA interference therapeutics, while Vertex discontinues a novel …
MaaT Pharma strengthens financial position to advance its microbiome-based therapies, focusing on acute graft-versus-host disease and hemato-oncology indications.
Viking Therapeutics and Bluejay Therapeutics highlight progress in obesity management and neurological disease treatment with key clinical milestones.
Merck’s global license deal for HRS-5346 and Tiziana’s intranasal foralumab Phase 2 trial signify strides in cardiovascular and …
Abbott receives FDA approval to begin Phase 3 trial of its Intravascular Lithotripsy system aimed at improving outcomes …
Alnylam Pharmaceuticals secures FDA clearance for vutrisiran, marking a significant milestone in RNA interference therapeutics for a rare …
Novartis receives a landmark approval for iptacopan (Fabhalta®), offering new hope for patients with a rare kidney disorder.
Precision BioSciences receives IND clearance to launch US-based trial of PBGENE-HBV, a meganuclease gene-editing candidate for a functional …
Positive safety and efficacy review by independent board positions MaaT013 as Europe’s potential first-approved microbiome-based drug for severe …
Already a subscriber? Log in